Abu Dhabi - The company plans to establish a specific sales network for Rivoceranib.
Published: Sat 2 Nov 2019, 9:21 PM
Updated: Sun 3 Nov 2019, 11:33 PM
Abu Dhabi based pharmaceutical manufacturer Neopharma and US based Elevar Therapeutics entered into an agreement to establish a joint venture in UAE with 50:50 partnership.
The company plans to establish a specific sales network for Rivoceranib, a targeted anticancer drug and conduct clinical trials for other pipeline candidates. Neopharma a global pharmaceutical company will undertake commercialising responsibility through its presence in various countries of Mena and India.
Suresh Kumar Nandiraju, Chief Operating Officer of Neopharma, said this joint venture is an embarking step to critical care complex oncology candidates and symbolises "our commitment" towards addressing unmet treatment needs of patients.
"We are very keen on expanding our immuno-oncology portfolio and Rivoceranib along with other pipeline molecules would strengthen our product offerings globally with a commitment to offer better life for patient."
Rivoceranib is the first successful small-molecule angiogenesis inhibitor in gastric cancer.
Rivoceranib acts by inhibiting angiogenesis, a critical process in cancer growth and proliferation. Specifically, Rivoceranib selectively inhibits VEGFR-2 which mediates the primary pathway for umor-mediated angiogenesis.
Rivoceranib has been clinically tested in over 1,000 patients worldwide and has demonstrated efficacy in numerous cancers including gastric cancer, CRC, HCC, NSCLC, esophageal cancer, thyroid cancer, mesothelioma, and neuroendocrine tumors. - business@khaleejtimes.com
E-Paper
Sign In
iPhone | iPad
Android
0°C 
